Most SOAP note examples online show a new problem: a patient arrives with a complaint, you work it up, and you reach a diagnosis. The follow-up visit for an established chronic condition is a different note, and it is the one nurse practitioner students actually write most often in primary care, yet it is the one that the examples rarely cover. A hypertension follow-up is not a fresh diagnostic puzzle; the diagnosis is already known. The work of the note is different: assessing control against a guideline target, deciding whether the current plan is working, and adjusting it. Get that framing wrong and the note reads like a thin re-run of an intake visit instead of the focused management document it should be.
This guide walks through a hypertension follow-up SOAP note built on the current 2025 ACC/AHA High Blood Pressure Guideline, showing what each section carries when the diagnosis is already established and the question is control. It assumes you know the basic SOAP structure; if you need that first, our guide to SOAP note fundamentals covers it. Every clinical figure here, the targets, thresholds, and drug classes, was verified against the current guideline at the time of writing, because a worked example is only useful if its numbers are right.
Quick Answer:
A hypertension follow-up SOAP note documents a return visit for an established diagnosis, so its focus is control, not diagnosis. Subjective: adherence, side effects, home BP readings, lifestyle, any symptoms. Objective: today's in-office BP (properly measured), relevant vitals, focused exam, and pertinent labs. Assessment: state whether the hypertension is controlled or uncontrolled against the guideline target of less than 130/80 mm Hg, with your reasoning. Plan: continue, titrate, or add therapy using the first-line classes (thiazide-type diuretic, long-acting dihydropyridine calcium channel blocker, ACE inhibitor, or ARB), set the follow-up interval, and reinforce lifestyle. The 2025 ACC/AHA guideline keeps the target at less than 130/80, uses the PREVENT risk score to guide when to start drugs, and recommends starting two agents (ideally a single-pill combination) for stage 2. Beta-blockers are not first-line for uncomplicated hypertension.
Why a Follow-Up Note Is Its Own Skill
A follow-up SOAP note has a different center of gravity from a new-problem note. In a new-problem visit, the assessment is a diagnostic conclusion reached from the history and exam. In a follow-up for an established condition, the diagnosis is a given, and the assessment becomes a judgment about status: is this condition controlled, at target, improving, or not, and does the plan need to change? That shift, from "what is this?" to "how is this going?", changes what every section has to carry.
This is a frequent stumbling point, because students trained on new-problem examples import the wrong emphasis. They re-document a full history of present illness as though the hypertension were newly discovered, or they write an assessment that simply restates the diagnosis without judging control. The assessment in a follow-up note has to reach a defensible verdict, controlled or uncontrolled against a specific target, and that verdict is the hinge the plan turns on. The discipline of making the assessment a reasoned judgment rather than a label is the same one our guide to the SOAP assessment section sets out, applied here to a chronic-disease target rather than a new diagnosis.
The 2025 Guideline You Are Measuring Against
A hypertension follow-up note is only as good as the standard it measures the patient against, so the current guideline is the backbone of the assessment and plan. The 2025 ACC/AHA/Multisociety High Blood Pressure Guideline reaffirms a treatment target of less than 130/80 mm Hg for most adults, keeping the threshold that the 2017 guideline established. The blood pressure categories are likewise unchanged: normal is below 120/80, elevated is 120 to 129 systolic and below 80 diastolic, stage 1 is 130 to 139 or 80 to 89, and stage 2 is 140 or above, or 90 or above. Knowing which category today's reading falls into is the first step of the assessment.
What the 2025 guideline updated is how you decide to start or intensify drug therapy. It uses the PREVENT equations, a 10-year cardiovascular risk estimate, to guide treatment for patients with stage 1 hypertension: for those at lower risk (PREVENT below 7.5 percent), a three-to-six-month trial of lifestyle change comes first, with medication added if the pressure stays at or above 130/80. Patients with stage 2 hypertension, or stage 1 with established cardiovascular disease, diabetes, chronic kidney disease, or high risk, start medication without waiting. The 2025 guideline as published in JACC is the authoritative source for these thresholds, and the table below summarizes what a follow-up note needs at hand.
Table 1: 2025 ACC/AHA Blood Pressure Categories and Treatment Thresholds
Category | Blood pressure | What a follow-up visit does |
|---|---|---|
Normal | Below 120/80 mm Hg | Reinforce lifestyle; routine re-check |
Elevated | 120-129 systolic and below 80 diastolic | Lifestyle change; monitor |
Stage 1 | 130-139 or 80-89 mm Hg | Lifestyle 3-6 months if low risk (PREVENT below 7.5%); start medication if high risk or if BP stays at or above 130/80 |
Stage 2 | 140 or above, or 90 or above | Start two first-line agents, ideally a single-pill combination |
Treatment target | Below 130/80 mm Hg | Judge control against this; intensify if above |
What Each Section Carries in a Follow-Up
The subjective section of a hypertension follow-up is focused, not exhaustive. It records adherence to the current regimen, any side effects (a dry cough on an ACE inhibitor, ankle swelling on a calcium channel blocker), home blood pressure readings if the patient monitors, lifestyle factors the plan depends on (sodium, alcohol, activity, weight), and any new symptoms. It does not re-tell the entire story of how the hypertension was first found; that belongs to the original visit, and importing it here is one of the commonest ways a follow-up note loses focus.
The objective section leads with today's blood pressure, and how it was measured matters as much as the number, because an improperly taken reading makes the entire assessment unreliable. It also records relevant vitals, a focused cardiovascular and volume-status exam, and any pertinent labs (electrolytes and renal function if the patient is on an ACE inhibitor, ARB, or diuretic). The clean separation between what you measured (objective) and what you conclude from it (assessment) is the same rule that governs every SOAP note, and it is worth being strict about it here, because the single blood pressure number sits in the objective section while the judgment about control belongs in the assessment. If this is a remote visit, the objective section also carries the telehealth-specific elements our telehealth SOAP note guide details, since a home reading and the visit modality both have to be documented.
The assessment states the verdict: hypertension, controlled or uncontrolled relative to the less-than-130/80 target, with the reasoning that connects today's reading, the home readings, and the trend to that conclusion. The plan then follows from the verdict: continue the current regimen if controlled, titrate the dose or add a second agent if not, always drawing from the first-line classes, set a follow-up interval, order any monitoring labs, and reinforce the lifestyle measures. A worked version of all four sections is laid out below.
Table 2: A Worked Hypertension Follow-Up SOAP Note
Section | What it contains for this visit |
|---|---|
Subjective | 58-year-old established patient with hypertension, here for routine follow-up. Reports good adherence to lisinopril, no cough or dizziness. Home readings averaging around 138/86. Diet higher in sodium recently; walks twice a week. No chest pain, headache, or visual change. |
Objective | In-office BP 142/88 (properly measured, seated, after rest), repeat 140/86. Heart rate 74, regular. No edema; heart and lung exam unremarkable. Recent basic metabolic panel within normal limits; potassium and renal function normal on current ACE inhibitor. |
Assessment | Hypertension, uncontrolled. In-office and home readings are above the target of less than 130/80 despite adherence to single-agent therapy. No signs of end-organ compromise today. The trend and current readings indicate the regimen needs intensification. |
Plan | Add a second first-line agent of a different class (long-acting dihydropyridine calcium channel blocker) to the existing ACE inhibitor. Reinforce sodium reduction and regular activity. Continue home BP monitoring with a log. Recheck electrolytes and renal function as appropriate. Follow up in 4 weeks to reassess control against target. |
Choosing and Adjusting Therapy
The plan section is where the guideline does its real work, so it helps to know the current first-line options cold. The 2025 guideline names four first-line drug classes for uncomplicated hypertension: thiazide-type diuretics, long-acting dihydropyridine calcium channel blockers, ACE inhibitors, and angiotensin receptor blockers. Beta-blockers are not first-line for uncomplicated hypertension, a point students frequently get wrong, and ACE inhibitors, ARBs, and direct renin inhibitors should not be combined with one another.
How you start or step up depends on the severity. For stage 1 hypertension, initiating a single first-line agent and titrating is reasonable; for stage 2, the guideline recommends starting with two first-line agents of different classes, ideally as a single-pill combination, because most patients need more than one drug and combination therapy improves both control and adherence. On a follow-up visit, the same logic drives intensification: if a patient on one agent is still above target, adding a second first-line agent from a different class is usually the next step rather than pushing a single drug to its ceiling. One notable 2025 update worth carrying into your reasoning is a strong recommendation to achieve a systolic pressure below 130 to reduce the risk of cognitive impairment and dementia, which strengthens the case for reaching the target rather than settling for "improved."
Writing chronic-disease notes and unsure if your plan matches the current guideline? |
|---|
The part that trips students up is not the SOAP structure; it is making the plan follow the current target and drug classes rather than an outdated one. Send us a follow-up note and a nursing reviewer will check your assessment and plan against the guideline in force, and show you where the reasoning needs tightening. Have your SOAP note reviewed, with an itemized quote back within 2 to 4 business hours, no obligation. |
Common Follow-Up Note Mistakes
A few errors recur in hypertension follow-up notes. The first is treating the note like a new diagnosis, re-documenting a full workup for a condition that is already established and known. The second is an assessment that names the diagnosis, but never judges control, leaving the reader unable to tell whether the plan should change. The third is measuring against an outdated target; notes still occasionally use the old 140/90 threshold, when the current guideline target is less than 130/80. The fourth is a plan that does not follow from the assessment, continuing an unchanged regimen for a patient who is clearly above target, with no rationale for the inaction.
The underlying fix for all of these is to let the guideline target structure the note. State today's category, judge control against less than 130/80, and make the plan a direct consequence of that judgment. A follow-up note built this way is short, focused, and defensible, which is exactly what a chronic-disease management visit calls for. The skill transfers directly to diabetes, heart failure, and every other condition you will follow over time, where the same control-then-adjust logic applies.
Frequently Asked Questions
What is the blood pressure target in the 2025 hypertension guideline?
The 2025 ACC/AHA High Blood Pressure Guideline reaffirms a treatment target of less than 130/80 mm Hg for most adults, the same threshold set in 2017. The blood pressure categories are also unchanged: normal is below 120/80, elevated is 120 to 129 systolic with diastolic below 80, stage 1 is 130 to 139 or 80 to 89, and stage 2 is 140 or above or 90 or above. In a follow-up note, you judge control against the less-than-130/80 target.
How is a follow-up SOAP note different from a new-problem note?
In a new-problem note, the assessment is a diagnostic conclusion reached from the history and exam. In a follow-up note for an established condition, the diagnosis is already known, so the assessment instead judges control or status, whether the condition is at target, and whether the plan needs to change. The subjective and objective sections are more focused, and the plan is usually a decision to continue, titrate, or add therapy rather than to start a workup.
What are the first-line drugs for hypertension in 2025?
The 2025 guideline names four first-line classes for uncomplicated hypertension: thiazide-type diuretics, long-acting dihydropyridine calcium channel blockers, ACE inhibitors, and angiotensin receptor blockers (ARBs). Beta-blockers are not first-line for uncomplicated hypertension. For stage 1, a single agent is reasonable; for stage 2, the guideline recommends starting two agents of different classes, ideally as a single-pill combination.
What is the PREVENT risk score, and why does it matter?
PREVENT is a 10-year cardiovascular risk estimate that the 2025 guideline uses to decide when to start drug therapy for stage 1 hypertension. A patient with stage 1 hypertension and lower risk (PREVENT below 7.5 percent) is offered a three-to-six-month trial of lifestyle change before medication, whereas someone at or above that risk threshold, or with stage 2 or established cardiovascular disease, diabetes, or chronic kidney disease, starts medication without waiting. It matters for a follow-up note because it justifies whether and when you intensify therapy.
How do I document blood pressure correctly in the objective section?
Record today's in-office reading with attention to proper measurement technique, since an improperly taken reading undermines the whole assessment. Include the value, relevant vitals, a focused cardiovascular and volume exam, and any home readings the patient reports. Keep the number itself in the objective section and reserve judgment about whether the pressure is controlled for the assessment, maintaining the separation between measured data and clinical conclusion that every SOAP note requires.
You May Also Find Useful
The Note Follows the Target
A hypertension follow-up SOAP note is a focused management document, not a repeat diagnosis. Anchor it to the current guideline target of less than 130/80, keep the subjective and objective sections tight and relevant to control, make the assessment a reasoned verdict on whether the patient is at target, and let the plan follow directly from that verdict using the first-line drug classes. Verify your figures against the current guideline rather than writing from memory, because chronic-disease targets and drug recommendations are exactly the kind of clinical detail that changes between guideline editions. A note built to the target is clear, current, and defensible, and the same structure carries into every chronic condition you will manage.
If you are learning to write chronic-disease follow-up notes and want yours reviewed against the current guideline, tell us what you are working on. You will receive an itemized quote within 2 to 4 business hours, with no obligation.
